Posted December 1, 2018 2:46 pm by Comments

The Nikkei Asian Review explores China’s rapid advances in the field of biotechnology, including gene editing and the use of AI and big data to predict a person’s likelihood of developing a given disease. As Chinese biotech startups push ahead in these areas, venture capital is pouring in from overseas. At the same time, however, scientists and policymakers in developed countries are questioning China’s adherence to ethical standards when it comes to such issues as human trials and access to personal data. READ MORE

Similar Posts:

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.